The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Dyskinesia Challenge, 2015Targeting M4 Muscarinic Receptors for the Treatment of Levodopa-induced Dyskinesia
Study Rationale:
Levodopa-induced dyskinesia is thought to stem from sustained stimulation of D1 dopamine receptors (D1Rs). One potential strategy for diminishing excessive D1R... -
Cognition Biomarkers, 2013Alpha-synuclein and Cognitive Decline in Parkinson’s Disease
Objective/Rationale:
Variability in the SNCA gene (which encodes alpha-synuclein, the protein that clumps in Parkinson’s disease) is a major risk factor for PD. Using next-generation... -
Rapid Response Innovation Awards, 2014Rating Segmental Progression of Cardinal Motor Symptoms in Early Parkinson's Disease
Objective/Rationale:
We recently reported a new, practical approach to rate segmental progression of cardinal motor symptoms in Parkinson's disease (PD) at early stages. We computed four new scores —... -
Research Grant, 2013Comprehensive Structural and Molecular Phenotyping of Parkinson’s Disease Models
Objective/Rationale:
Parkinson’s disease (PD) pre-clinical models carrying relevant human PD gene mutations can provide important insights into the molecular mechanisms implicated in PD... -
Access to Data and Biospecimens, 2014Contribution of the Unfolded Protein Response to Idiopathic and LRRK2-driven Parkinson’s Disease
Objective/Rationale:
The unfolded protein response (UPR) is a life-death switch that instructs aged and overworked cells to self-destruct. We hypothesize that hyper-activation of the UPR... -
Research Grant, 2014Role of LRRK2 in Alpha-synuclein-induced Neurodegeneration: Supplement
Promising Outcomes of Original Grant:
We seek to develop a robust and standardized pre-clinical model relevant to late-onset Parkinson’s disease (PD) that will identify clinically viable LRRK2 kinase...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.